Dr. Giri on Genes that Carry a Risk for Prostate Cancer

Video

Veda Giri, MD, associate professor, Thomas Jefferson University Hospital, discusses genes that are associated with a risk of developing prostate cancer.

Veda Giri, MD, associate professor, Thomas Jefferson University Hospital, discusses genes that are associated with a risk of developing prostate cancer.

The genes that have had the greatest association of risk for prostate cancer are BRCA1/2. BRCA2 has been associated with aggressive prostate cancer. HOXB13 is another hereditary prostate cancer gene that doesn’t have a role in guiding management for advanced or metastatic disease, but does seem to confer some of the highest risks for prostate cancer. How to incorporate it into screening is also being studied, says Giri.

Other DNA mismatch-repair genes such as MLH1, MSH2, PMS2, MSH6 that are linked with Lynch syndrome, a hereditary colon cancer syndrome, can also be very important in terms of considering clinical trials for men with advanced prostate cancer.

Additional genes in the repair pathways are also of importance, particular in men with metastatic disease in terms of guiding their treatment, states Giri. The current NCCN guidelines have expanded beyond BRCA1/2 to PALB2 and FANCA. Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital hosted a consensus conference in which experts expanded the genetic testing for men with prostate cancer and included genes like ATM and the DNA mismatch-repair genes.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,